Lifesize Teams With Voicera to Elevate Meeting Productivity
AI Assistant Eva Makes Meetings Actionable
LAS VEGAS, June 06, 2018 (GLOBE NEWSWIRE) -- INFOCOMM - Lifesize®, a global innovator of video collaboration and meeting productivity solutions, is teaming with Voicera to bring an in-meeting artificial intelligence (AI) assistant to Lifesize video and audio calls. Once in the meeting, the AI assistant Eva will take notes and create a searchable, actionable transcript, enabling customers to elevate their meeting productivity.
"Imagine how effective and efficient your meetings would be if someone else was taking the notes and sharing action items directly after," said Craig Malloy, CEO of Lifesize. "Adding Voicera's AI assistant to your Lifesize meeting is just the beginning. Expect to see all Lifesize solutions utilize AI as it matures to make video conferencing more immersive and collaborative."
"Adding AI to your video calls is the next logical step to empower meaningful conversations and make your meetings more actionable," said Cory Treffiletti, Chief Marketing Officer of Voicera. "Voicera created Eva to do just that. With Eva listening in and pulling out important moments from your Lifesize HD video calls, your meetings become even more productive."
Using Eva is simple. Just invite Eva to any Lifesize video or audio meeting. Eva will take notes and capture important action items. The meeting transcript is sent immediately after the meeting ends and is easily shared, searched, edited and stored for later reference.
See this technology in action at InfoComm 2018 (June 6-8 in Las Vegas) alongside many other innovations by visiting Lifesize at booth N2434 .
At Lifesize, we understand the power of connecting people to make the workplace great. For more than a decade, Lifesize has been at the forefront of video conferencing and collaboration, delivering high-quality solutions designed to bring people together. We combine a best-in-class, cloud-based video conferencing service, with award-winning, easy-to-use smart devices designed for any conference room so you can connect to anyone, anywhere. It's a meeting experience like no other. Our video conferencing solutions are designed for the demands of today's modern enterprise, yet fully accessible to businesses of any size. For more information, visit www.lifesize.com or follow the company @LifesizeHD.
Lifesize and the Lifesize logo are trademarks of Lifesize, Inc. and may be registered. All other trademarks are the property of their respective owners.
Voicera leverages A.I. to harness the power of voice in the workplace and connect what happens in meetings to the rest of the collaboration workflow. Voicera does this via Eva, your Enterprise Virtual Assistant. Eva is an in-meeting assistant that listens, takes notes and identifies actions from your meetings. Eva surfaces value in person-to-person conversations and enables that value to be shared through the rest of the enterprise. Headquartered in Menlo Park, Ca., Voicera is led by veterans from Oracle, Facebook, and LinkedIn. The company received $20MM in venture funding from leading investors including Battery Ventures, Cisco Investments, e.ventures, GGV Capital, Greycroft, GV (formerly Google Ventures), Microsoft Ventures, Salesforce Ventures and Workday Ventures. For more information on Voicera, or to experience an Eva-powered meeting, visit Voicera or download the iOS or Android apps.
Media Relations: Maria Galler, Lifesize Matt Burrows, The Hoffman Agency PR@lifesize.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LifeSize, Inc. via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30 | Pressmeddelande
LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma
Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15 | Pressmeddelande
BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio
Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05 | Pressmeddelande
WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public
Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00 | Pressmeddelande
OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to
Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29 | Pressmeddelande
ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern
Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30 | Pressmeddelande
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum